Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the
The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While
Poolbeg Pharma plc (LON:POLB) a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that its Scientific Advisory Board (‘SAB’) has endorsed the influenza drug targets identified in its
Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic
Organoids – living, 3D multicellular models of human organs – could revolutionize early research and discovery of new medicines. Because organoids mirror human biology more closely than animal models like
Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement Poolbeg Pharma (LON:POLB,
The pharmaceutical industry has long been at the forefront of scientific innovation, driving advancements in medicine that aim to improve the quality of human health and lifespan. The race to
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
